This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

A Discussion of 2 Double-Blind Studies Comparing Risperidone and Quetiapine in Patients With Schizophrenia

Georges M. Gharabawi, MD; Cynthia A. Bossie, PhD; Gahan J. Pandina, PhD; Mary J. Kujawa, MD; Andrew J. Greenspan, MD; and Young Zhu, PhD

Published: February 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We read with great interest the recent article by Zhong and colleagues1 reporting results of a trial comparing quetiapine and risperidone for the treatment of schizophrenia. In that double-blind, 8-week study, there was a statistically significant difference favoring risperidone on the change at endpoint on the Positive and Negative Syndrome Scale (PANSS) positive symptoms subscale (an a priori secondary efficacy measure). In the same month, we2 published similar findings from a double-blind, placebo-controlled trial comparing these 2 atypical antipsychotics in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization (least squares mean ± SE change from baseline to endpoint of the monotherapy phase for PANSS positive symptoms: -8.7 ± 0.5 with risperidone and -5.9 ± 0.5 with quetiapine; p < .01).' ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: